These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 32169314)
1. Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8. Huddart R; Hall E; Lewis R; Porta N; Hussain SA; James ND Eur Urol; 2020 Jun; 77(6):e156-e157. PubMed ID: 32169314 [No Abstract] [Full Text] [Related]
2. Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8. Liu W; Liu X; Li S Eur Urol; 2020 Jun; 77(6):e154-e155. PubMed ID: 32113660 [No Abstract] [Full Text] [Related]
3. Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15. Hussain SA; Porta N; Hall E; Qureshi M; Lewis R; Huddart R; James ND Eur Urol; 2021 Aug; 80(2):e51-e52. PubMed ID: 34053780 [No Abstract] [Full Text] [Related]
4. Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15. Sundar S; Symonds P Eur Urol; 2021 Aug; 80(2):e49-e50. PubMed ID: 34024651 [No Abstract] [Full Text] [Related]
5. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Huddart RA; Hall E; Lewis R; Porta N; Crundwell M; Jenkins PJ; Rawlings C; Tremlett J; Campani L; Hendron C; Hussain SA; James ND; Eur Urol; 2020 Feb; 77(2):260-268. PubMed ID: 31843338 [TBL] [Abstract][Full Text] [Related]
6. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Tan WS; Kelly JD; Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948 [No Abstract] [Full Text] [Related]
7. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Tan WS; Mustard C; Kelly JD; Eur Urol; 2023 Feb; 83(2):e48-e49. PubMed ID: 36456403 [No Abstract] [Full Text] [Related]
8. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. Hall E; Hussain SA; Porta N; Lewis R; Crundwell M; Jenkins P; Rawlings C; Tremlett J; Sreenivasan T; Wallace J; Syndikus I; Sheehan D; Lydon A; Huddart R; James N; Eur Urol; 2022 Sep; 82(3):273-279. PubMed ID: 35577644 [TBL] [Abstract][Full Text] [Related]
9. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203 [No Abstract] [Full Text] [Related]
10. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Campodonico F; Mattioli F; Introini C Eur Urol; 2023 Feb; 83(2):e56-e57. PubMed ID: 36372625 [No Abstract] [Full Text] [Related]
11. Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation. Giacalone NJ; Niemierko A; Shipley WU; Efstathiou JA Eur Urol; 2017 Sep; 72(3):e64-e65. PubMed ID: 28642020 [No Abstract] [Full Text] [Related]
12. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Vila-Reyes H; Joel DeCastro G; McKiernan JM Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798 [No Abstract] [Full Text] [Related]
13. Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62. Lindgren MS; Jensen JB Eur Urol; 2021 May; 79(5):e137. PubMed ID: 33593653 [No Abstract] [Full Text] [Related]
14. Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802. Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F Eur Urol; 2013 Jan; 63(1):e7-8. PubMed ID: 23092542 [No Abstract] [Full Text] [Related]
15. Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81. Tosoian JJ; Trock BJ; Ballentine Carter H; Mamawala M Eur Urol; 2017 Jan; 71(1):e13. PubMed ID: 27311363 [No Abstract] [Full Text] [Related]
16. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940 [No Abstract] [Full Text] [Related]
17. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Li R; Spiess PE; Gilbert SM; Necchi A Eur Urol; 2019 Aug; 76(2):e34. PubMed ID: 31056228 [No Abstract] [Full Text] [Related]
18. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9. Goonewardene SS; Persad R; Young A; Makar A Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269 [No Abstract] [Full Text] [Related]
19. Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature? Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka NA; Höglund M; Ullén A; Liedberg F Eur Urol; 2022 Apr; 81(4):e92-e93. PubMed ID: 35039183 [No Abstract] [Full Text] [Related]
20. Reply to Yi Zhou, Weigang Yan, and Hanzhong Li's Letter to the Editor re: Eduard Baco, Erik Rud, Lars Magne Eri, et al. A Randomized Controlled Trial to Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol 2016;69:149-56. Baco E; Rud E; Vlatkovic L Eur Urol; 2016 Aug; 70(2):e55. PubMed ID: 26852076 [No Abstract] [Full Text] [Related] [Next] [New Search]